Psoriasis: What Every Nurse Practitioner Needs to Know

08/01/17 Expiration Date: 12/01/17

Jointly provided by

DANNEMILLER Healthcare Education and National Nurse Practitioner Symposium

Intended Audience
Nurse Practitioners, Nurse Midwives and Physician Assistants in acute and primary care roles.

Learning Objectives
Upon completion of this activity, the participant should be able to:

• Identify three immunopathogenic targets associated with psoriasis pathogenesis.
• Identify five therapeutic options for the treatment of mild, moderate and severe psoriasis.
• Identify five comorbidities associated with psoriatic disease.

Statement of Need
Psoriasis is common, immune-mediated condition with numerous comorbidities that every NP, regardless of their practice specialty, needs to understand. According to the American Academy of Dermatology, 7.5 million people in the United States have psoriasis. It is primarily seen in adults, but occurs in all age groups. Up to 40% of people with psoriasis experience joint inflammation that produces symptoms of arthritis. Psoriasis and psoriatic arthritis can be associated with other diseases and conditions, including diabetes, cardiovascular disease and depression. In 2013, the total direct cost of treatment associated with psoriasis was estimated to be between $51.7 billion and $63.2 billion. Most nurse practitioners do not get a comprehensive dermatology review in their graduate or undergraduate curriculums. This session will provide a comprehensive overview of psoriasis pathogenesis and therapeutic regimens.

Accreditation Statement(s)
Physicians

In support of improving patient care, this activity has been planned and implemented by Dannemiller and National Nurse Practitioner Symposium. Dannemiller is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Dannemiller designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Dannemiller and National Nurse Practitioner Symposium. Dannemiller is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education.

Provider number: 090419. This program is accredited for 1.5 contact hour(s) which includes 0.75 hours of pharmacology.

Nurses
Dannemiller designates this enduring material for 1.5 contact hour(s).

Method of Participation
Participants should first read the objectives and other introductory CME/CE information and then proceed to the educational activity. To receive your contact/CE hours view the presentation video, and complete and pass a 10-question test on the presentation content (80% is considered passing).

Credit is provided through December 1, 2017. No credit will be given after this date. If you attended the 2017 National Nurse Practitioner Symposium, these enduring materials hours are complimentary and separate from the contact/CE hours you received at the live meeting. If you did not attend the 2017 National Nurse Practitioner Symposium, the cost is $5 per test attempt. If you are not successful in passing a test on first attempt, you may retake the same test after a 24 hour grace period, which allows you time to review the presentation video again.

Faculty
Lakshi M. Aldredge, MSN, RN, ANP-BC
Dermatology Nurse Practitioner, VA Portland Healthcare System; Portland OR

Disclosures
In accordance with the Accreditation Council for Continuing Medical Education (ACCME), Dannemiller requires that any person who is in a position to control the content of a CME/CE activity must disclose all financial relationships they have with a commercial interest.

The following faculty members have the following financial relationships with commercial interests:
Lakshi M. Aldredge, MSN, RN, ANP-BC is a Consultant/Advisory Board and on the Speaker Bureau for AbbVie, Lilly, Novartis and Celgene.

Bernard Abrams, MD content reviewer; Jennifer Hodge, Project Manager, Dannemiller; and NNPS coordinating staff have no financial relationships with commercial interests.

To resolve identified/potential conflicts of interest, the educational content was fully reviewed by a member of the Dannemiller Clinical Content Review Committee who has nothing to
disclose. The resulting certified activity was found to provide educational content that is current, evidence based and commercially balanced.

Off-label statement
Off label statement provided: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Dannemiller or National Nurse Practitioner Symposium. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject